Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
NCT02398461Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Apr 2015
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing rHIgM22 with Placebo (2 arms). Primary endpoint: Number of patients with Adverse Events at 180 days. Started Apr 2015; status: completed.
02
Drugs
rHIgM22
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02398461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398461.